All Stories

  1. UNDER-RECOGNITION OF MENOPAUSE-RELATED SYMPTOMS AND TREATMENT PATTERNS: A CROSS-SECTIONAL SURVEY OF WOMEN
  2. Role of IL-13 in allergic rhinitis inflammation: Preliminary results
  3. The dual role of inflammation and tertiary lymphoid structures in tumor progression and immunity: a literature review and our experience
  4. Assessing Intestinal Inflammation: A Comparison of Immunochromatographic Tests and ELISA for Fecal Calprotectin Detection
  5. Time series analysis and modelling of MIS-C cases: can we predict MIS-C cases by new cases in the 0–18 age group?
  6. Markers for the Severity of Multisystem Inflammatory Syndrome in Children: A Multivariate Analysis
  7. Neurological manifestations of MIS-C: a single-center experience and case-based literature review
  8. CAR T-cell therapy in systemic lupus erythematosus: a scoping review
  9. Gene expression of cytokines IL-17 and IL-33 in plasma and nasal lavage fluid of patients with allergic rhinitis and bronchial asthma
  10. Three years post-pandemic of SARS-CoV-2: Insights from a Bulgarian online survey
  11. Emerging Therapeutic and Inflammation Biomarkers: The Role of Meteorin-Like (Metrnl) and Follistatin-Like 1 (FSTL1) in Inflammatory Diseases
  12. The challenges in symptomatic therapy of post-COVID-19: a Bulgarian cohort study
  13. Cardiometabolic improvements, sleep apnea reduction, and biomarker modulation under dual GLP-1RA and SGLT2i therapy: a prospective study
  14. Editorial: Bridging science and innovation advances in diagnosis, therapy, and translational medicine
  15. Integrated Evaluation of CPAP Therapy in Type 2 Diabetic Patients with Sleep Apnea: Quality of Life and Effects on Metabolic Function and Inflammation in Outpatient Care
  16. Immunological Strategies for Enhancing Viral Neutralization and Protection in Antibody-Guided Vaccine Design
  17. Rare sporadic endolymphatic sac tumors: A case report and literature review
  18. Effects of SGLT2 Inhibitors on Sleep Apnea Parameters and Cheyne–Stokes Respiration in Patients with Acute Decompensated Heart Failure: A Prospective Cohort Study
  19. Targeted Treatment Approaches for Gastrointestinal Metastases of Malignant Melanoma: Clinical Insights and Overcoming Drug Resistance
  20. New Players in Metabolic Syndrome
  21. MicroRNAs in Systemic Sclerosis: Involvement in Disease Pathogenesis and Potential Use as Diagnostic Biomarkers and Therapeutic Targets
  22. Potential for Misinterpretation in the Laboratory Diagnosis of Clostridioides difficile Infections
  23. Quality of Life and Mental Health in Patients with Exacerbated Heart Failure: The Role of Obstructive and Central Sleep Apnea Phenotypes
  24. Regulatory T cell-based therapies for type 1 diabetes: a narrative review
  25. Integrating Primary Care and Specialized Therapies in Rheumatoid Arthritis: Optimizing Recognition, Management, and Referral Practices
  26. Nasopharyngeal Colonization and Antimicrobial Susceptibility of Bacterial Isolates in Children and Young Adults with Acute, Protracted, and Chronic Cough: A Cross-Sectional Bulgarian Study
  27. GENETIC ASPECTS OF AGING AND FERTILITY
  28. Preclinical and Clinical Data on Current Therapeutic Options for Micro- and Macrovascular Abnormalities in Systemic Sclerosis
  29. Targeting CD3-CD16+CD56+ NK Cells and NK Cell Activity by Intralipid in the Management of Reproductive Failure
  30. Serum podocalyxin levels in patients with obesity and carbohydrates disorders
  31. Complicated Pneumonia in a Child: Hydropneumothorax Associated with MIS-C and GAS Superinfection
  32. Management of Coronary Artery Diseases in Systemic Vasculitides: Complications and Strategies
  33. Biomacromolecules as Immunomodulators: Utilizing Nature’s Tools for Immune Regulation
  34. Lung Involvement in Systemic Sclerosis—From Pathogenesis to Prediction
  35. Nutritional Management and Physical Activity in the Treatment of Sarcopenic Obesity: A Review of the Literature
  36. Mucosal Immunity and Trained Innate Immunity of the Gut
  37. Dietary Supplements as Concentrated Sources of Nutrients with a Nutritional or Physiological Effect for Children with Inflammatory Bowel Disease
  38. Primary Signet-Ring-Cell Carcinoma in the Colorectum: A Case-Based Literature Review
  39. Biomacromolecules As Immunomodulators: Utilizing Nature’s Tools for Immune Regulation
  40. Exploring the Role of the Microbiome in Rheumatoid Arthritis—A Critical Review
  41. Exploring Gut–Brain Interaction Disorders: Mechanisms and Translational Therapies Crossing Neurology to Gastroenterology
  42. In the Pursuit of Precision: Novel Target Therapies Revolutionizing SLE Care
  43. Cytokine Signatures in Inflamed Mucosa of IBD Patients: State-of-the-Art
  44. p16 Expression in Multinucleated Stromal Cells of Fibroepithelial Polyps of the Anus (FEPA): A Comprehensive Review and Our Experience
  45. Characteristics of emerging new autoimmune diseases after COVID‐19 vaccination: A sub‐study by the COVAD group
  46. Expanding the role of CAR T‐cell therapy: From B‐cell hematological malignancies to autoimmune rheumatic diseases
  47. Listening to patients, for the patients: The COVAD Study—Vision, organizational structure, and challenges
  48. Autoantibodies related to ataxia and other central nervous system manifestations of gluten enteropathy
  49. New Biomarkers for Systemic Necrotizing Vasculitides
  50. Collating the voice of people with autoimmune diseases: Methodology for the Third Phase of the COVAD Studies
  51. Breakthrough SARS-CoV-2 infection and disease flares in patients with rheumatoid arthritis: result from COVAD e-survey study
  52. Characteristics of and risk factors for COVID-19 breakthrough infections in idiopathic inflammatory myopathies: results from the COVAD study
  53. Aortic Elasticity and Cardiovascular Risk Stratification: A Narrative Review on the Current Understanding
  54. Eosinophilic Cationic Protein and Immunoglobulin E: Unraveling Biomarkers in Chronic Pediatric Cough
  55. Immunogenicity and Loss of Effectiveness of Biologic Therapy for Inflammatory Bowel Disease Patients Due to Anti-Drug Antibody Development
  56. New strategies in the diagnosis and treatment of immune-checkpoint inhibitor-mediated colitis
  57. Chemerin in Obese Patients with Nonalcoholic Fatty Liver Disease with or without Prediabetes
  58. Meteorin-like Protein and Zonulin in Polycystic Ovary Syndrome: Exploring Associations with Obesity, Metabolic Parameters, and Inflammation
  59. Navigating the Cytokine Seas: Targeting Cytokine Signaling Pathways in Cancer Therapy
  60. Impaired health-related quality of life in idiopathic inflammatory myopathies: a cross-sectional analysis from the COVAD-2 e-survey
  61. Cardiovascular Manifestations of Multisystem Inflammatory Syndrome in Children: A Single-Center Bulgarian Study
  62. Role of Specific Autoantibodies in Neurodegenerative Diseases: Pathogenic Antibodies or Promising Biomarkers for Diagnosis
  63. Interleukin-6: Unravelling its role in sarcopenia pathogenesis and exploring therapeutic avenues
  64. COVID-19 breakthrough infections in type 1 diabetes mellitus: a cross-sectional study by the COVID-19 Vaccination in Autoimmune Diseases (COVAD) Group
  65. Navigating the Challenges of Gluten Enteropathy and Infertility: The Role of Celiac-Related Antibodies and Dietary Changes
  66. Relationship of serum Fetuin-A with metabolic and vascular parameters in patients with prediabetes and type 2 diabetes mellitus
  67. Flares of autoimmune rheumatic disease following COVID‐19 infection: Observations from the COVAD study
  68. Microbiome and Genetic Factors in the Pathogenesis of Liver Diseases
  69. Blood Coagulation and Thrombotic Disorders following SARS-CoV-2 Infection and COVID-19 Vaccination
  70. Applications of time series analysis in epidemiology: Literature review and our experience during COVID-19 pandemic
  71. SARS-CoV-2 Variant-Specific Gastrointestinal Symptoms of COVID-19: 2023 Update
  72. Gender differences in patient experience in idiopathic inflammatory myopathies: Subanalysis from the COVAD dataset
  73. Effectiveness and safety of COVID-19 vaccines in patients with oncological diseases: State-of-the-art
  74. Multinucleated giant cells of bladder mucosa are modified telocytes: Diagnostic and immunohistochemistry algorithm and relation to PD-L1 expression score
  75. High Concordance of CT Colonography and Colonoscopy Allows for the Distinguishing and Diagnosing of Intestinal Diseases
  76. Type 1 diabetes, COVID‐19 vaccines and short‐term safety: Subgroup analysis from the global COVAD study
  77. Correlates of breakthrough COVID-19 in vaccinated patients with systemic sclerosis: survival analysis from a multicentre international patient-reported survey
  78. Endothelial Dysfunction and Pregnant COVID-19 Patients with Thrombophilia: A Narrative Review
  79. COVID-19 vaccine safety during pregnancy and breastfeeding in women with autoimmune diseases: results from the COVAD study
  80. Long-term effectiveness, outcomes and complications of bariatric surgery
  81. The End or a New Era of Development of SARS-CoV-2 Virus: Genetic Variants Responsible for Severe COVID-19 and Clinical Efficacy of the Most Commonly Used Vaccines in Clinical Practice
  82. Clinical and Laboratory Manifestation of Gastrointestinal Involvement in MIS-C: A Single-Center Observational Study
  83. Genetic and Epigenetic Factors in Risk and Susceptibility for Childhood Asthma
  84. High fatigue scores in patients with idiopathic inflammatory myopathies: a multigroup comparative study from the COVAD e-survey
  85. In Silico Probiogenomic Characterization of Lactobacillus delbrueckii subsp. lactis A4 Strain Isolated from an Armenian Honeybee Gut
  86. POS0573 COMORBIDITIES, COMPLEX MULTIMORBIDITY AND PROMIS HEALTH OUTCOMES AMONGAUTOIMMUNE RHEUMATIC DISEASES: DATA FROM THE COVAD STUDY
  87. OP0082 COVID-19 VACCINE SAFETY DURING PREGNANCY AND BREASTFEEDING IN WOMEN WITH AUTOIMMUNE DISEASES: RESULTS FROM THE COVAD STUDY
  88. POS0558 FLARES OF AUTOIMMUNE RHEUMATIC DISEASE FOLLOWING COVID-19 INFECTION: OBSERVATIONS FROM THE COVAD STUDY
  89. POS1231 IMPAIRED HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES: A CROSS-SECTIONAL ANALYSIS FROM AN INTERNATIONAL E-SURVEY
  90. POS1216 MULTIMORBIDITY AND PROMIS HEALTH OUTCOMES IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES: DATA FROM A LARGE, GLOBAL E-SURVEY (COVAD STUDY)
  91. POS0273 POST COVID-19 SYNDROME IN PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASES: RESULTS FROM THE COVAD STUDY
  92. POS1254 REDUCED HEALTH-RELATED QUALITY OF LIFE USING PROMIS IN PATIENTS WITH SYSTEMIC SCLEROSIS: A CROSS-SECTIONAL ANALYSIS FROM THE INTERNATIONAL COVAD-2 E-SURVEY
  93. AB1295 SAFETY AND TOLERANCE OF ANTI-SARS-CoV-2 VACCINES IN SJÖGREN'S SYNDROME: RESULTS FROM THE COVAD STUDY
  94. Editorial: Recent advances and new biomarkers in ulcerative colitis
  95. AB1312 MYOSITIS PATIENTS WITHOUT AUTOIMMUNE MULTIMORBIDITY AT LOWER RISK OF DELAYED ONSET COVID-19 VACCINE ADVERSE EVENTS THAN OTHER AUTOIMMUNE DISEASES: RESULTS FROM THE COVAD STUDY
  96. Future of prostate imaging: Artificial intelligence in assessing prostatic magnetic resonance imaging
  97. Global disparities in the treatment of idiopathic inflammatory myopathies: results from an international online survey study
  98. Anandamide is associated with waist-to-hip ratio but not with Body Mass Index in women with polycystic ovary syndrome
  99. Flares in IIMs and the timeline following COVID-19 vaccination: a combined analysis of the COVAD-1 and -2 surveys
  100. EPIGENETIC ALTERATIONS IN GENE EXPRESSION IN THE AGING IMMUNE SYSTEM
  101. Flares after COVID-19 infection in patients with idiopathic inflammatory myopathies: results from the COVAD study
  102. Systemic sclerosis and COVID-19 vaccine safety: short-term insights from the global COVID-19 vaccination in autoimmune disease (COVAD) survey
  103. COVID-19 related liver injuries in pregnancy
  104. Flares in autoimmune rheumatic diseases in the post-COVID-19 vaccination period—a cross-sequential study based on COVAD surveys
  105. Gut Microbiome Composition and Its Metabolites Are a Key Regulating Factor for Malignant Transformation, Metastasis and Antitumor Immunity
  106. Retroperitoneal and abdominal bleeding in anticoagulated COVID-19 hospitalized patients: Case series and brief literature review
  107. Pain in individuals with idiopathic inflammatory myopathies, other systemic autoimmune rheumatic diseases, and without rheumatic diseases: A report from the COVAD study
  108. Intravenous Immunoglobulins as Immunomodulators in Autoimmune Diseases and Reproductive Medicine
  109. Vaccine hesitancy decreases in rheumatic diseases, long-term concerns remain in myositis: a comparative analysis of the COVAD surveys
  110. Changes in Patterns of Infectivity and Mortality with SARS-CoV-2 Omicron Variant in Bulgaria
  111. COVID-19 Vaccines for Adults and Children with Autoimmune Gut or Liver Disease
  112. Immunomodulators Containing Epicor, Colostrum, Vitamin D, Zinc, Lactobacilli and Bifidobacterium Reduce Respiratory Exacerbations in Children and Adults with Chronic Pulmonary Diseases
  113. Safety and tolerance of vaccines against SARS-CoV-2 infection in systemic lupus erythematosus: results from the COVAD study
  114. COVID-19 vaccination in autoimmune diseases (COVAD) study: vaccine safety and tolerance in rheumatoid arthritis
  115. COVID-19 severity and vaccine breakthrough infections in idiopathic inflammatory myopathies, other systemic autoimmune and inflammatory diseases, and healthy controls: a multicenter cross-sectional study from the COVID-19 Vaccination in Autoimmune Dise...
  116. Effectiveness and safety of COVID-19 vaccines in patients with diabetes as a factor for vaccine hesitancy
  117. Prevalence and Risk Factors of Gastroesophageal Reflux Disease in Bulgaria: An Internet-Based Survey
  118. COVAD survey 2 long-term outcomes: unmet need and protocol
  119. COVID‐19 Vaccination in Autoimmune Diseases (COVAD) study: Vaccine safety in idiopathic inflammatory myopathies
  120. Impaired physical function in patients with idiopathic inflammatory myopathies: results from the multicentre COVAD patient-reported e-survey
  121. COVID-19 vaccination-related adverse events among autoimmune disease patients: results from the COVAD study
  122. POS0201 COVID-19 SEVERITY AND VACCINE BREAKTHROUGH INFECTIONS IN IDIOPATHIC INFLAMMATORY MYOPATHIES, OTHER SYSTEMIC AUTOIMMUNE AND INFLAMMATORY DISEASES, AND HEALTHY INDIVIDUALS: RESULTS FROM THE COVID-19 VACCINATION IN AUTOIMMUNE DISEASES (COVAD) STUDY.
  123. POS1260 COVID-19 VACCINATION-RELATED ADVERSE EVENTS AMONG AUTOIMMUNE DISEASE PATIENTS: RESULTS FROM THE COVID-19 VACCINATION IN AUTOIMMUNE DISEASES (COVAD) STUDY
  124. POS0899 HIGH FATIGUE SCORES IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES: A MULTIGROUP COMPARATIVE STUDY FROM THE COVAD E-SURVEY.
  125. POS0855 IMPAIRED PROMIS PHYSICAL FUNCTION IN IDIOPATHIC INFLAMMATORY MYOPATHY PATIENTS: RESULTS FROM THE MULTICENTER COVAD PATIENT REPORTED E-SURVEY
  126. OP0161 TREATMENT PATTERNS OF IDIOPATHIC INFLAMMATORY MYOPATHIES: RESULTS FROM AN INTERNATIONAL COHORT OF OVER 1,400 PATIENTS
  127. Vaccine Hesitancy in Patients with Autoimmune Diseases: Data from the Coronavirus Disease-2019 Vaccination in Autoimmune Diseases Study
  128. Nutritional Management of Thyroiditis of Hashimoto
  129. Food Sensitization Impact on Asthma Attacks in Children According to Age Group
  130. Cellular, Antibody and Cytokine Pathways in Children with Acute SARS-CoV-2 Infection and MIS-C—Can We Match the Puzzle?
  131. Specific Immunoglobulin E and G to Common Food Antigens and Increased Serum Zonulin in IBS Patients: A Single-Center Bulgarian Study
  132. COVID-19 Delta Wave Caused Early Overburden of Hospital Capacity in the Bulgarian Healthcare System in 2021
  133. Immune titers of protection against severe acute respiratory syndrome coronavirus 2: are we there yet?
  134. Interferon-gamma release assays outcomes in healthy subjects following BNT162b2 mRNA COVID-19 vaccination
  135. Alterations of gut bacteria Akkermansia muciniphila and Faecalibacterium prausnitzii in late post-transplant period after liver transplantation
  136. Omentin-1 and diabetic foot
  137. Elevated levels of interleukin-18 are associated with several indices of general and visceral adiposity and insulin resistance in women with polycystic ovary syndrome
  138. Estimating COVID Case Fatality Rate in Bulgaria for 2020–2021
  139. Atopic Status in Children with Asthma and Respiratory Allergies—Comparative Analysis of Total IgE, ImmunoCAP Phadiatop/fx5 and Euroimmun Pediatric Immunoblot
  140. Liver dysfunction as a cytokine storm manifestation and prognostic factor for severe COVID-19
  141. Markers of Endothelial Inflammation and Repair in a Group of Patients with ANCA-associated Vasculitis
  142. COVID-19 vaccination in autoimmune disease (COVAD) survey protocol
  143. Genetic variation of TGF-ΒR2 as a protective genotype for the development of colorectal cancer in men
  144. DYNAMICS OF CHILDHOOD RESPIRATORY INFECTIONS DURING THE COVID-19 PANDEMIC: THE EFFECT OF QUARANTINE АND BEYOND
  145. MY LIFE AS A RESEARCHER AND EDUCATOR
  146. Liver Involvement in Children with COVID-19 and Multisystem Inflammatory Syndrome: A Single-Center Bulgarian Observational Study
  147. Surgical complications in COVID-19 patients in the setting of moderate to severe disease
  148. Gastrointestinal mucosal immunity and COVID-19
  149. Foremost Concepts in Mechanisms of De Novo Post-Liver Transplantation Malignancy
  150. Neopterin in the Evolution from Obesity to Prediabetes and Newly Diagnosed Type 2 Diabetes
  151. INFECTION-ACQUIRED VERSUS VACCINE-INDUCED IMMUNITY AGAINST COVID-19
  152. Biomarkers in Irritable Bowel Syndrome: Biological Rationale and Diagnostic Value
  153. Immunological and microRNA Features of Allergic Rhinitis in the Context of United Airway Disease
  154. Antibiotic-Related Changes in Microbiome: The Hidden Villain behind Colorectal Carcinoma Immunotherapy Failure
  155. SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis
  156. Targeting Inflammatory Cytokines to Improve Type 2 Diabetes Control
  157. Laboratory Assessment of Disease Activity in Pediatric Patients with Inflammatory Bowel Disease: What’s New?
  158. Increased PD-L1 expression in high-grade bladder cancer with squamous cell differentiation in Bulgarian and French patients' samples
  159. What could microRNA expression tell us more about colorectal serrated pathway carcinogenesis?
  160. Lumican in Obese Patients with Nonalcoholic Fatty Liver Disease With or Without Prediabetes
  161. Left Ventricular Function Assessed by Myocardial Deformation and Torsion in Chronic Hemodialysis Patients
  162. A review on the evolution of immunotherapy in bladder carcinoma
  163. Relationship between circulating netrin-1 levels, obesity, prediabetes and newly diagnosed type 2 diabetes
  164. Identification of Specific IgE Antibodies and Asthma Control Interaction and Association Using Cluster Analysis in a Bulgarian Asthmatic Children Cohort
  165. Chemical Metabolism of Xenobiotics by Gut Microbiota
  166. Lactobacilli Supplemented with Larch Arabinogalactan and Colostrum Stimulates an Immune Response towards Peripheral NK Activation and Gut Tolerance
  167. AB0020 CORRELATION BETWEEN SERUM AND SYNOVIAL CONCENTRATION OF IL-17A AND MIRNA EXPRESSION IN RHEUMATOID ARTHRITIS PATIENTS
  168. Impact of testosterone treatment on circulating irisin in men with late-onset hypogonadism and metabolic syndrome
  169. Retraction notice to “Alterations in cytokine gene expression profile in colon mucosa of inflammatory bowel disease patients on different therapeutic regimens” [Cytokine 92 (2017) 12–19]
  170. Interleukin-6 compared to the other Th17/Treg related cytokines in inflammatory bowel disease and colorectal cancer
  171. Epidemiological and Morphological Characteristics of Urothelial Bladder Cancer in a Bulgarian and a French Sample of Patients
  172. Challenges and updates in the management of eosinophilic esophagitis
  173. Suppression of autoreactive T and B lymphocytes by anti-annexin A1 antibody in a humanized NSG murine model of systemic lupus erythematosus
  174. Peroxiredoxin 4 levels in patients with PCOS and/or obesity
  175. The association between retinol-binding protein 4 and prediabetes in obese patients with nonalcoholic fatty liver disease
  176. Serum Periostin Levels in Patients with Moderate to Severe Persistent Bronchial Asthma
  177. Serum levels of IL-5, IL-6, IL-8, IL-13 and IL-17A in pre-defined groups of adult patients with moderate and severe bronchial asthma
  178. Trefoil Factor 3 is Highly Predictive of Complete Mucosal Healing Independently and in Combination with C-Reactive Protein in Patients with Ulcerative Colitis
  179. Celiac-Related Autoantibodies and IL-17A in Bulgarian Patients with Dermatitis Herpetiformis: A Cross-Sectional Study
  180. P100 Systemic and local IL-17A and miR-146A levels in rheumatoid arthritis patients
  181. P101 Systemic and local IL-17A and miR-155 levels in rheumatoid arthritis patients
  182. Effect of Diode Laser Treatment on the Level of IL‑6 in the Gingival Crevicular Fluid in Patients with Chronic Periodontitis
  183. P099 Patients with ulcerative colitis show increased Treg number in peripheral blood after 1 year of anti-TNF therapy
  184. Higher levels of IL-18 in patients with prediabetes compared to obese normoglycaemic controls
  185. Higher levels of thioredoxin interacting protein (TXNIP) in patients with prediabetes compared to obese normoglycemic subjects
  186. Interactions of allergic rhinitis and bronchial asthma at mucosal immunology level
  187. Serum levels of IL-5, IL-6 and IL-8 in moderate and severe asthma clusters
  188. Predictors of severe exacerbations in patients with moderate and severe asthma
  189. Th17 cells in Bulgarian children with chronic obstructive lung diseases
  190. Soluble CD14 is Associated with Disease Activity and Severity in Chronic Viral Hepatitis C and B
  191. AB0078 Systemic and local il-17a and mir-223 levels in rheumatoid arthritis patients
  192. MCP-1/CCL2 in a Bulgarian Cohort of Children with Bronchial Asthma and Cystic Fibrosis
  193. Dynamics of Some Routine Immunological Parameters During Anti - TNF Therapy in Patients with Crohn’s Disease
  194. Serological Update on Celiac Disease Diagnostics in Adults
  195. Extraintestinal Manifestations and Intestinal Complications in Patients with Crohn's Disease: Associations with Some Clinico-Laboratory Findings, Immunological Markers and Therapy
  196. Interleukin-18 serum level is elevated in type 2 diabetes and latent autoimmune diabetes
  197. Reduced soluble Toll-like receptors 2 in type 2 diabetes
  198. Cartilage oligomeric protein, matrix metalloproteinase-3, and Coll2-1 as serum biomarkers in knee osteoarthritis: a cross-sectional study
  199. 516 Dermatitis herpetiformis in Bulgaria: Report of 78 patients
  200. Serum levels of IL-6 in adult patients with moderate to severe asthma
  201. AB0170 Diminished peripheral t-cell activation along with marked th17 circulating profile in ssc
  202. Reduced level of soluble TLR2 in type 2 diabetes despite increased TLR2 monocyte expression
  203. Alterations in cytokine gene expression profile in colon mucosa of Inflammatory Bowel Disease patients on different therapeutic regimens
  204. 03.04 Serum and synovial concentration of calprotectin in rheumatoid arthritis patients
  205. 03.07 Serum and synovial concentration of il-17a in rheumatoid arthritis patients
  206. Increased kallistatin levels in patients with obesity and prediabetes compared to normal glucose tolerance
  207. Phenotypes Determined by Cluster Analysis in Moderate to Severe Bronchial Asthma
  208. Treg/Th17 cell balance and phytohaemagglutinin activation of T lymphocytes in peripheral blood of systemic sclerosis patients
  209. Prevalence of Positive Diabetes-Associated Autoantibodies among Type 2 Diabetes and Related Metabolic and Inflammatory Differences in a Sample of the Bulgarian Population
  210. Cytokines in Inflamed Mucosa of IBD Patients
  211. Increased peroxiredoxin 4 levels in patients with prediabetes compared to normal glucose tolerance subjects
  212. Myostatin and carbohydrate disturbances
  213. AB0637 Markers of Endothelial Inflammation and Repair in a Group of Patients with Systemic Vasculitis
  214. P-178 YI Specific mRNA Expression Profile in Inflamed Colonic Mucosa Derived from Patients with Inflammatory Bowel Disease
  215. Cells Isolated from Human Glioblastoma Multiforme Express Progesterone-Induced Blocking Factor (PIBF)